Combinations of antibody-TKI currently being investigated for the treatment of EGFR Ex20ins NSCLC patients include cetuximab, necitumumab and amivantamab in combination with different second- and third-generation EGFR TKIs. Here, EGFR is linked to non-small cell lung carcinoma.